Also known as: LY3841136 · LY-3841136
Eloralintide is Eli Lilly's once-weekly, selective amylin receptor (AMY1R) agonist for obesity, engineered to avoid activity at the calcitonin receptor. Phase 2 data showed up to 20% mean placebo-adjusted weight loss at 48 weeks with predominantly mild GI side effects; Phase 3 (ENLIGHTEN-1) began enrolling in 2026.
In the Phase 2 trial, once-weekly subcutaneous eloralintide at 1, 3, 6, and 9 mg produced mean weight reductions of roughly 9%, 12%, 18%, and 20% respectively at 48 weeks, versus 0.4% with placebo — with nausea and fatigue as the dominant adverse events and no signal of the muscle-mass loss associated with some incretin therapies. It is being studied both as monotherapy and as a complementary add-on to incretin (GLP-1/GIP) therapy.
Phase 3 (ENLIGHTEN-1) started in 2026 and is expected to run through at least 2028. Not yet FDA-approved.
Eloralintide is a fatty-acid-acylated analog of human amylin, engineered for selective binding at the AMY1R complex (human AMY1R EC50 23.9 pM) over the related AMY3R and calcitonin receptors.
Amylin receptor agonism acts centrally at the area postrema and hypothalamus to reduce food intake, slow gastric emptying, and suppress glucagon secretion — a satiety mechanism distinct from, and potentially additive to, GLP-1/GIP incretin agonism.
Eloralintide is being developed both as monotherapy and as a complementary add-on to incretin (GLP-1/GIP) therapy. It is investigational only — not commercially available, and no consumer-grade sourcing should be considered safe or authentic.
As an amylin-pathway agonist still in Phase 3 trials, no real-world cycling data exists outside controlled studies.
Investigational — not yet FDA-approved. Long-term safety beyond the current trial duration (through 2028) is not yet established.
Investigational, Phase 3 (ENLIGHTEN-1, ongoing). Structure includes a Cys2–Cys7 methylene thioacetal bridge and 3 non-coded residues, so its sequence is not representable in standard one-letter amino-acid code. Not yet FDA-approved.
Ask anything about Eloralintide — mechanisms, dosing protocols, interactions, or research comparisons.
Semaglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Ozempic) and chronic weight management (…
Tirzepatide (Mounjaro/Zepbound) is the first FDA-approved dual GIP/GLP-1 receptor agonist, developed by Eli Lilly. It pr…
AOD-9604 is a modified fragment of human growth hormone (hGH residues 177–191) with an added N-terminal tyrosine residue…
Cagrilintide (AM833) is a long-acting amylin analogue developed by Novo Nordisk. It mimics the satiety and gastric-empty…